BofA analyst Michael Cherny lowered the firm’s price target on GoodRx to $8 from $9.50 and keeps a Buy rating on the shares. The firm is increasing its FY23 revenue and adjusted EBITDA estimates to reflect Q3 results, while decreasing its FY24 revenue and adjusted EBITDA estimates to reflect the uncertain variables around partnership programs.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on GDRX: